Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

Purpose Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. Methods Patients with advanced solid mal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer chemotherapy and pharmacology 2017-07, Vol.80 (1), p.29-36
Hauptverfasser: Abou-Alfa, Ghassan K., Lewis, Lionel D., LoRusso, Patricia, Maitland, Michael, Chandra, Priya, Cheeti, Sravanthi, Colburn, Dawn, Williams, Sarah, Simmons, Brian, Graham, Richard A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. Methods Patients with advanced solid malignancies and hepatic impairment were enrolled into one of four cohorts: normal [bilirubin (bili) 
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-017-3315-8